A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on June 6-7, 2021 with the following interim recommendations made:

• Non-live recombinant herpes zoster vaccine – be granted Schedule II status
• Bisacodyl, when sold in strengths of 5mg or less per oral dosage unit, in package sizes containing no more than 105 mg of bisacodyl – be granted Unscheduled Status
• Bisacodyl, when sold in strengths of 10 mg or less per rectal dosage unit/suppository, in package sizes containing no more than 50 mg of bisacodyl – remain Unscheduled
• Bisacodyl and its salts, except when sold in strengths of 5 mg or less per oral dosage unit in package sizes containing no more than 105mg of bisacodyl and except when sold in strengths of 10mg or less per rectal dosage unit/suppository in package sizes containing no more than 50mg of bisacodyl – remain in Schedule III

Any objections to these interim recommendations must be received by the NAPRA office by end of day July 15, 2021. Questions or comments should be directed to the NDSAC Secretariat via email at ndsac@napra.ca.